Market News

Abbott Labs (ABT)

Abbott’s Ibis technology for detecting and characterizing a vast array of microorganisms has been named one of the top innovations in 2009 by The Scientist magazine.
Abbott’s Ibis system (now marketed under the PLEX ID trade name) was recognized for the honor, in part, because it is designed to detect and characterize a broad range of microorganisms in a given sample, including viruses, bacteria and fungi.

Dec 7 · 2:51:00 PM · Source: PR USA
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Pfizer (PFE)

Pfizer said Tuesday it had reached an agreement to license the worldwide rights to a treatment for Gaucher disease, a rare genetic disorder, from Protalix, an Israeli biotechnology company.
This deal would put Pfizer into competition with Cerezyme, Genzyme’s biggest-selling product.

Dec 1 · 12:32:00 PM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Covidien Ltd. (COV)

Covidien, a medical device company, said Tuesday that it posted net profit of $56 million, or 11 cents a share, for the fiscal fourth quarter ended Sept. 25, compared with $409 million, or 84 cents a share, a year earlier. Net results were reduced by a variety of charges related to various divestitures and acquisitions.

Nov 17 · 12:09:00 PM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb will continue to pursue acquisitions, the drug maker's financial chief said, with its war chest bolstered this week by a $1.75 billion cash infusion from a debt refinancing by its Mead Johnson Nutrition Co. (MJN).
By the end of this year, Bristol-Myers expects to have gross cash of more than $10 billion and more than $2 billion in net cash, factoring in the company's debt,

Nov 14 · 4:07:00 PM · Source: The Wall Street Journal
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Cadence Pharmaceuticals Inc. (CADX)

Cadence Pharmaceuticals, said Friday the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of the New Drug Application (NDA) for intravenous (IV) acetaminophen by three months. The extended PDUFA goal date is February 12, 2010.
The company said it remains confident in its NDA submission and will continue to work closely with the FDA toward the potential approval of intravenous acetaminophen, noting it is now planning for a launch early in the second quarter of 2010.

Nov 13 · 11:34:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb and Alder Biopharmaceuticals announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.
Under the terms of the collaboration agreement, Alder will grant to Bristol-Myers Squibb worldwide exclusive rights to develop and commercialize ALD518 for all potential indications except cancer, for which Alder will retain rights and grant Bristol-Myers Squibb an option to co-develop and commercialize outside the United States. An upfront cash payment of $85 million, potential development-based and regulatory-based milestone payments of up to $764 million across a range of indications, potential sales-based milestones which, under certain circumstances, may exceed $200 million, and royalties on net sales are payable to Alder by Bristol-Myers Squibb.

Nov 12 · 5:02:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb and ZymoGenetics presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients. Antiviral activity was observed at all dose levels tested.
“There is a strong need for additional options for hepatitis C patients,” said Brian Daniels, M.D., senior vice president, Global Development & Medical Affairs, Bristol-Myers Squibb. “We are pursuing this investigational pathway to address the fact that although current interferons have been the backbone of therapy with meaningful efficacy, they are often poorly tolerated, leading to dose reductions, poor compliance and avoidance of treatment.”

Nov 12 · 4:53:00 PM · Source: Business Wire · Related: ZymoGenetics Inc.
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb and Exelixis reported phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
The study evaluates the safety, tolerability, and clinical activity of XL184 at continuous daily doses of 175 mg or 125 mg in patients with previously treated GBM, including some patients who had received prior antiangiogenic therapy.

Nov 12 · 4:49:00 PM · Source: Business Wire · Related: Exelixis Inc.
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Previous · Next